Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13810 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Jocelyn Courville und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology-Drug Development Solution, ICON plc, Blue Bell, Pennsylvania, USA. Hauptthemen laut MEDLINE: Drug Labeling, Protein Binding. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
One of the key pharmacokinetic properties of most small molecule drugs is their ability to bind to serum proteins. Unbound or free drug is responsible for pharmacological activity while the balance between free and bound drug can impact drug distribution, elimination, and other safety parameters. In the hepatic impairment (HI) and renal impairment (RI) clinical studies, unbound drug concentration is often assessed; however, the relevance and impact of the protein binding (PB) results is largely limited. We analyzed published clinical safety and pharmacokinetic studies in subjects with HI or RI with PB assessment up to October 2022 and summarized the contribution of PB results on their label dose recommendations. Among drugs with HI publication, 32% (17/53) associated product labels include PB results in HI section. Of these, the majority (9/17, 53%) recommend dose adjustments consistent with observed PB change. Among drugs with RI publication, 27% (12/44) of associated product labels include PB results in RI section with the majority (7/12, 58%) recommending no dose adjustment, consistent with the reported absence of PB change. PB results were found to be consistent with a tailored dose recommendation in 53% and 58% of the approved labels for HI and RI section, respectively. We further discussed the interpretation challenges of PB results, explored treatment decision factors including total drug concentration, exposure–response relationships, and safety considerations in these case examples. Collectively, comprehending the alterations in free drug levels in HI and RI informs treatment decision through a risk‐based approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology-Drug Development Solution, ICON plc, Blue Bell, Pennsylvania, USA.
- Clinical Pharmacology, Pharmacokinetics, Worldwide Clinical Trials, Austin, Texas, USA.
- Clinical Pharmacology-Drug Development Solution, ICON plc, Langen, Germany.
ORCID-Profile: Jocelyn Courville, Gerhard Arold
Zitieren
APA
Courville, J., Roupe, K., & Arold, G. (2024). Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions. Clinical and Translational Science. https://doi.org/10.1111/cts.13810
Vancouver
Courville J, Roupe K, Arold G. Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions. Clinical and Translational Science. 2024. doi:10.1111/cts.13810
BibTeX
@article{Courville2024,
author = {Courville, Jocelyn and Roupe, Kathryn and Arold, Gerhard},
title = {Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13810}
}
EUVIMED